Floyd E. Bloom M.D. — Co-Founder and Director at Alkermes

Dr. Floyd E. Bloom, M.D., is a Co-Founder of Alkermes Inc. Dr. Bloom served as the Chairman and Chief Executive Officer of Neurome Inc. Dr. Bloom has been active in Neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health and The Salk Institute. He serves as a Director of Elan Pharmaceuticals, Inc. and has been a Director of Alkermes plc since September 2011. He served as Director of Alkermes, Inc. from 1987 to September 2011. Dr. Bloom serves as Director of Antler Science Two Ltd. He serves as a Member of the Scientific and Industry Advisory Board of RiverVest Venture Partners, LLC. Dr. Bloom serves as Member of the Scientific Advisory Board at RxGen Inc., and Psylin Neurosciences, Inc. He has been a Member of Scientific Advisory Board at aTyr Pharma Inc., since October 14, 2009. Dr. Bloom serves as Member of Scirus Scientific Advisory Board - Medicine at Elsevier B.V. He serves as a Member of Medical and Scientific Advisory Board at NeuroVentures Capital LLC and NeuroVentures Fund, L.P. and the Scientific Advisory Boards of Neogene and Digital Gene Technology. Dr. Bloom serves as Trustee of The Corey Bloom Family Trust and Floyd E Bloom Charitable Remainder Trust. He is also a Member of the National Academy of Science, the Institute of Medicine and the Royal Swedish Academy of Science. Since 1983, he has been at The Scripps Research Institute (TSRI), where he is a Member of the President's Council on Bioethics and is Professor Emeritus in the Molecular and Integrative Neuroscience Department. He served as the Chairman of Advancis Pharmaceutical Corp. Dr. Bloom served as the Chairman of Middlebrook Pharmaceuticals, Inc. He served as Scientific Advisory Board of MiddleBrook Pharmaceuticals, Inc. Dr. Bloom served as Member of Science & Technology Committee at Elan Corporation, plc from July 1, 2007 to July 16, 2009. He served as a Member of the Scientific Advisory Boards of Merck, Inc., Glaxo/Smithkline, Elan Pharmaceuticals, Prothena, Inc. and Saegis Pharmaceuticals, Inc. Dr. Bloom also served as an Editor-in-Chief of Science Magazine from May 1995 to June 2000 and has authored or co-authored more than 25 books and monographs and more than 400 original research articles. He was previously the Chairman of the Department of Neuropharmacology at TSRI, a Director of Behavioral Neurobiology at The Salk Institute and Chief of the Laboratory of Neuropharmacology at the National Institute of Mental Health (NIMH). Dr. Bloom also served as a Member and Chairman of Neurobiology Section at The National Academy of Sciences. He was also the Chairman of the National Council at Washington University in St. Louis School of Medicine. Dr. Bloom has received numerous awards, including the Pasarow Award for Neuropsychiatry, the Herman von Helmholtz Award, the Sarnat Award for Mental Health Research, as well as a number of honorary degrees from major universities. He was also one of the first Neurobiologists to utilize modern molecular biological techniques in a search for molecules of importance in brain function and the characterization of brain specific genes. Dr. Bloom has investigated comprehensive eneurotransmitter systems at the anatomical, physiological and pharmacological levels. He has conducted correlative studies of the noradrenergic innervation of cerebellum and cerebral cortex. Dr. Bloom recognized the value of computers in neuroscience and pioneered their application to neuro-anatomic investigations and the development of a neuro-anatomic database. His work has found considerable applicability to many enigmatic disorders of the nervous system, such as the addictive states, the dementias and the major psychoses. Dr. Bloom completed United States Public Health Service Commissioned Corps special Post-Doctoral Fellowship at Yale University. He holds an M.D. (Alpha Omega Alpha) from Washington University School of Medicine in St. Louis and an A.B. (Phi Beta Kappa) from Southern Methodist University.